


CLAIMS

What is claimed is:

- 5 1. A compound of Formula I, and pharmaceutically acceptable salts thereof,



Formula I

10 wherein:

R₁ is -(CR^aR^b)_n-X;

R^a, R^b are each independently selected from the group consisting of H, C₁₋₆ alkyl;
 15 each of said C₁₋₆ alkyl being optionally substituted with one to six same or different halogen;

X is H or C₁₋₆ alkyl; said C₁₋₆ alkyl being optionally substituted with a member
 20 selected from the group consisting of (1) one to six same or different halogen or hydroxy, (2) heteroaryl, (3) non-aromatic heterocyclic ring and (4) a member selected from Group A;

n is 1-6;

25 Group A is a member selected from the group consisting of halogen, CN, OR^x, N⁺R^cR^dR^e[T], NR^cR^d, COR^c, CO₂R^x, CONR^xR^y and S(O)_mR^c;
 R^x and R^y are independently H or C₁₋₆ alkyl;
 R^c, R^d and R^e are independently C₁₋₆ alkyl;

m is 0-2


T⁻ is halogen, CF₃SO₃⁻ or CH₃SO₃⁻;


5 R₂ and R₅ are independently halogen or H;

R₃ and R₄ are each independently selected from the group consisting of H, halogen and C₁₋₆ alkyl; said C₁₋₆ alkyl can be optionally substituted with one to six same or different halogen;

10

Q is a member selected from the group consisting of





F₁ is CH or N;

- 5 R₆ is selected from the group consisting of H, halogen, NR^fR^g, SRⁿ and a five-membered heteroaryl containing one to two of the same or different heteroatoms selected from the group consisting of O, S and N;

10 R^f and R^g are independently H, C₁₋₆ alkyl or C₁₋₆ alkyl; said C₁₋₆ alkyl optionally substituted with OR^h or CO₂R^h;

R^h and Rⁱ are independently H or C₁₋₆ alkyl;

15 Rⁿ is C₁₋₆ alkyl optionally substituted with CO₂R^h;

R₇ is H, or CO₂R^h;

R₈ is H, COR^h, CO₂R^h or C₁₋₆ alkyl; said C₁₋₆ alkyl optionally substituted with OR^h;

20 R₉ is H, halogen, heteroaryl, phenyl, phenyl substituted with a halogen group, phenyl substituted with a methanesulfonyl group, COR^h, CO₂R^h, C₁₋₆ alkyl,

C₂₋₆ alkenyl, and C₂₋₄ alkynyl; said C₂₋₄ alkynyl optionally substituted with C₁₋₆ cycloalkyl;

R₁₀ and R₁₁ are independently H, NO₂ or NR^hRⁱ

5

R₁₂ is H, CO₂R^h or C₁₋₂ alkyl; said C₁₋₂ alkyl optionally substituted with phenyl;

R₁₃ and R₁₄ are independently selected from the group consisting of H, OR^h, CONR^jR^k, NR^lR^m and pyrrolidine; wherein said pyrrolidine is attached at the
10 nitrogen atom;

R^j and R^k are independently H or C₁₋₆ alkyl optionally substituted with phenyl;

R^l and R^m are independently C₁₋₆ alkyl;

15

R₁₅ and R₁₆ are independently selected from the group consisting of H, OR^h, phenyl, pyridyl and C₁₋₆ alkyl; said C₁₋₆ alkyl optionally substituted with CO₂R^h;

R₁₇ and R₁₈ are independently selected from the group consisting of halogen,
20 NR^lR^m, SR^h and morpholine; wherein said morpholine is attached at the nitrogen atom;

R₁₉ is selected from the group consisting of H, phenyl, C₂₋₆ alkenyl and C₁₋₆ alkyl; said C₁₋₆ alkyl optionally substituted with one to six same or different halogen,
25 CO₂R^h, CONR^hRⁱ, pyridyl and one to three phenyl groups; wherein in the case of C₁₋₆ alkyl substituted with one phenyl group, said phenyl group is optionally substituted with a member selected from the group consisting of halogen, PO(OR^h)₂, CO₂R^h, SO₂Rⁿ and CONR^hRⁱ;

30 Rⁿ is C₁₋₆ alkyl;

R₂₀ and R₂₁ are independently H or halogen;

R₂₂ is C₁₋₆ alkyl;

R₂₃ and R₂₄ are independently H or C₁₋₆ alkyl;

5

R₂₅ is C₁₋₆ cycloalkyl or C₁₋₆ alkyl; said C₁₋₆ alkyl group optionally substituted with a member selected from the group consisting of CO₂R^h, PhCO₂R^h and one to six same or different halogens;

10 R₂₆ is selected from the group consisting of H, halogen, C₁₋₆ alkyl; C₂₋₆ alkenyl, OR^h and COR^h; said C₂₋₆ alkenyl being optionally substituted with OR^h;

R₂₇ is H, OR^h or CO₂R^h;

15 R₂₈ is CO₂R^h;

R₂₉ is H or halogen;

heteroaryl is a 5- or 6-membered aromatic ring containing at least one and up to
20 four non-carbon atoms selected from the group consisting of O, N and S;

non-aromatic heterocyclic ring is a 3 to 7-membered non-aromatic ring
containing at least one and up to four non-carbon atoms selected from the group
consisting of O, N and S; and

25

p is 0-2.

2. A compound of claim 1 wherein heteroaryl is selected from the group
consisting of pyridyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-
30 oxadiazol-5-one and tetrazole.

3. A compound of claim 1 wherein non-aromatic heterocyclic ring is selected from the group consisting of pyrrolidine and piperidine.

4. A compound of claim 1 wherein:

5

R^a and R^b are hydrogen.

5. A compound of claim 1 wherein:

10 R_1 is $-(CH_2)_n-X$ and n is 2-4.


6. A compound in claim 1 wherein R_3 and R_4 are each independently selected from the group consisting of H, fluorine and C_{1-2} alkyl; said C_{1-2} alkyl being optionally substituted with one to three fluorine atoms.

15

7. A compound in claim 1 wherein:

R_1 is 3-methyl-2-butyl or $-(CH_2)_n-X$; wherein n is 2-4;

20 X is a member selected from the group consisting of $-F$, $-CN$, $-SR^c$, $-SO_2R^c$, $-OR^x$, $-COR^c$, CO_2R^x , $CONR^xR^y$, $[NR^cR^dR^e][T^-]$,



R^c , R^d and R^e are independently C_{1-4} alkyl; and

R^x and R^y are independently H or C_{1-4} alkyl.

8. A compound of claim 1 wherein:

5

R_2 and R_5 are independently H.

9. A method for treating mammals infected with RSV, and in need thereof, which comprises administering to said mammal a therapeutically effective
10 amount of one or more of the aforementioned compounds as claimed in any one of claims 1-8.

10. A pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned compounds as claimed in
15 any one of claims 1-8, and a pharmaceutically acceptable carrier.